As a result, GLP-1 RAs are not recommended for patients with a personal or family history of multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B), or medullary thyroid cancer [7,23,31,32]. This evidence concerns the gene GLP1R and multiple endocrine neoplasia type 2A.